Records 1 - 2 (of 2 Records) |
Query Trace: Res Sq[original query] |
---|
SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough
Petra, Mlcochova et al. Res Sq 2021 10.21203/rs.3.rs-637724/v1
Summary:
Vaccine breakthrough infections in a cohort of healthcare workers at 3 centers in India were predominantly B.1.617.2 (Delta) (98/133). Compared to wild-type (WT Wuhan-1), B.1.617.2 showed an approximate 8-fold reduction in vaccine-elicited antibody production. Serum neutralizing titers were lower in participants vaccinated with ChAdOx-1 (Oxford/AstraZeneca) compared to BNT162b2 (Pfizer/BioNTech) (GMT 654 vs. 3372, p = .0006).
Visit Weekly CDC COVID-19 Science Update site for the full summary.
|
Long Covid after Breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19
Ziyad, Al-Aly et al. Res Sq 2021 10.21203/rs.3.rs-1062160/v1
Key findings:
|
Disclaimer: The purpose of the CDC COVID-19 Science
Update is to share public health articles with public health agencies
and departments for informational and educational purposes. Materials
listed in this Science Update are selected to provide awareness of
relevant public health literature. A material’s inclusion and the
material itself provided here in full or in part, does not necessarily
represent the views of the U.S. Department of Health and Human
Services or the CDC, nor does it necessarily imply endorsement of
methods or findings. While much of the COVID-19 literature is open
access or otherwise freely available, it is the responsibility of the
third-party user to determine whether any intellectual property rights
govern the use of materials in this Science Update prior to use or
distribution. Findings are based on research available at the time of
this publication and may be subject to change.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 03, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure